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thical core issues in research with human sub-
jects are related to risk-benefit assessment and informed
consent. This is valid for all types of studies. However, at
least in former times, there was a much greater focus of
ethical considerations on controlled clinical trials than
on naturalistic trials. A major reason could have been
that controlled clinical trials that aim at the efficacy and
safety of a new (therapeutic or diagnostic) intervention
may have unknown and perhaps severe somatic risks,
whereas naturalistic studies seem not to intervene, but
only to observe and analyze phenomena in a population
or in data of routinely recorded findings, and thereby are
assumed to have almost no risks. At least the weight of
ethical implications is differently accentuated, more with
potential physical risks in the former, and with potential
psychological consequences of the observational proce-
dures and confidentiality of recorded data in the latter. 
Whereas controlled trials have clearly established pro-
cedures including the obligation to obtain a vote from
the competent ethics committee (EC) or institutional
review board (IRB), naturalistic trials are performed by
a much broader set of various procedures, for many of
which and in some countries the consultation of an EC
is not obligatory but at best only recommended,
although selection of participants and application of
questionnaires and interviews are interventions in their
lives with potential psychological consequences.
1
The following examples of controlled as well as of natu-
ralistic trials will demonstrate the need for a thorough
ethical evaluation of the risk-benefit assessment and of
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Ethical core issues in research with human subjects are
related to informed consent and risk-benefit assessment.
This is valid for all types of studies. However, there has
been much greater focus of ethical considerations on con-
trolled clinical trials than on naturalistic trials, probably
because the former are interventional in nature and may
have unknown and perhaps severe somatic risks, whereas
naturalistic studies seem not to intervene but only to
observe, and therefore are assumed to have fewer or
almost no risks. However, there are also ethical implica-
tions in naturalistic trials, although their weight is differ-
ently accentuated, more with potential, more with poten-
tial psychological burdens of the observational procedures
and more with potential physical risks in interventional tri-
als. This will be elaborated with examples of placebo-con-
trolled trials and of incidental findings in screenings, of
marketing influences on observational studies, and of psy-
chological burdens by survey interviews. The ethical impli-
cations will be analyzed within a more general frame-
work. Finally, recommendations will be offered.   
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informed consent in order to protect the participant with
regard to the ethical principles respect for his or her
autonomy, welfare, nonmaleficence, and confidentiality.
Examples
Controlled clinical trials 
Controlled clinical trials, especially in the form which up
to now has been the gold standard, ie, the double-blind
randomized controlled clinical trial (RCCT) are
research studies for the proof of efficacy and safety of a
new intervention. Objective influences on the outcome
of a specific intervention are controlled by randomizing
the allocation of research subjects to the index group
and to the control group, and subjective influences by
blinding the patient and—if necessary—the researcher
(double-blinding). However, the more the sample of
research subjects is selected according to strong inclu-
sion and exclusion criteria, the less the generalizability
of results will be. Therefore, the result of the same inter-
vention in nonselected samples from routine practice
may differ, and justifies additional trials under natural-
istic conditions. 
Two controversially debated ethical issues are placebo-
controlled trials and the “therapeutic misconception.”
Placebo-controlled trials
The revision of article 29 of the Helsinki Declaration in
2000 and its “Note of Clarification” in 2002 on the use of
placebo controls in cases of an existing standard treat-
ment provoked a heated controversy between advocates
of an “active control orthodoxy” as opposed to those of
a “placebo orthodoxy.” 
2 The former argue that with-
holding a proven standard therapy is unethical and vio-
lates the ethical principle of nonmaleficence, whereas
the latter defend the position that placebo controls are
necessary to evidence the efficacy of a new intervention
in cases, in which the efficacy of an established standard
treatment is supplied only by historical and clinical expe-
rience. The discussion was intensified a decade ago also
by the usage of purely placebo-controlled RCCTs in
patients with schizophrenia, and resulted in the opera-
tionalization of a set of criteria for an ethically accept-
able use of placebos in controlled trials of patients for
whom a standard therapy is available.
3 Further pro argu-
ments are high placebo rates in the field of indication, a
high risk of side effects of the standard treatment, or its
efficacy on only single symptoms.
4,5 Particularly contro-
versial was the debate about placebo controls in depres-
sion: whereas some argue for their indispensability
6,7 in
order to avoid ostensible evidence by equivalence with
an inefficient standard treatment, others are convinced
of the efficacy of antidepressant drugs, especially in
severe depression.
8,9 Efficacy is less evident in mild
depression. Therefore, placebo-controlled trials in
depressed patients may be considered only: (i) if the
objective of the trial cannot be achieved by any other
design, eg, by a trial of superiority with a standard treat-
ment as comparator
10; (ii) in patients with mild depres-
sion, eg, in samples from which all patients with severe
depression with high risks, for example, suicidality, or
with intense individual suffering are excluded; (iii) if the
placebo control is added onto a standard treatment; (iv)
if the patient is fully informed and competent to give
consent.
11
The ethical consequences are that researchers as well as
ECs
12 are obliged to assess comprehensively the
risk:benefit ratio in order to establish whether the
advantage of the placebo application is greater than its
risks. They must examine precisely the pros and cons of
the study (eg, “me-too-trials,” noninferiority or superi-
ority trials),
10 and the definition of the clinical conditions
of the study sample (eg, severe or mild depression, ther-
apy resistance). They must guarantee that the research
patient will be informed clearly and comprehensively
and has the capacity to consent.
Therapeutic misconception
Ethically important is a patient’s misconception of
research as care, ie, “to confuse the design and conduct
of research with personalised medical care.” 
13 This sit-
uation was labelled 25 years ago “therapeutic miscon-
ception” (TM).
14 Recently this concept has been con-
troversially discussed. It was suggested that the term TM
supports the “assumption that clinical trial participation
disadvantages research participants as compared with
receiving standard medical care”
13 as well as the
reproach that some of its newer interpretations “exag-
gerate the distinction between research and treat-
ment.”
15 But such statements were clearly repudiated by
the inventors of the term, who stated:
Our concerns about TM's impact on informed consent do
not derive from the belief that research subjects have
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poorer outcomes than persons receiving ordinary clinical
care. Rather, we believe that subjects with TM cannot give
an adequate informed consent to research participation,
which harms their dignitary interests and their abilities to
make meaningful decisions. …In the absence of empirical
studies on the steps required to dispel TM and the impact
of such procedures on subject recruitment, it is premature
to surrender to the belief that TM must be widely tolerated
in clinical research.
16 An investigation by these latter
authors resulted in the conclusion that “subjects often sign
consents to participate in clinical trials with only the most
modest appreciation of the risks and disadvantages of par-
ticipation.” 
17
The ethical consequence is the necessity to be sure that
patients as potential research participants have under-
stood the differences between clinical research trials and
clinical care.
Naturalistic trials
Naturalistic trials are either prospective “noninterven-
tional” observational studies of phenomena, eg, real-
world events or conditions, or retrospective analyses of
existing data from other studies, eg, follow-ups of treated
patients, or routinely documented basic data. Prototypes
are cohort studies or case-control studies as well as
screenings or surveys. 
In general naturalistic trials have no individual benefit
but do have potential risks, mainly psychic burdens such
as worries or stigmatization by (i) the selection of cases,
eg, family members in genetic risk studies with regard to
information and consent; (ii) the method of observation
and assessment, eg, by interview with intimate questions;
(iii) data confidentiality, eg, in epidemiological studies;
(iv) “interventions” in marketing trials called “observa-
tional or utilization studies.” 
Major ethical aspects are: method and content of infor-
mation for consent, data confidentiality; dealing with
incidental findings.
Observational trials
Up to the 1990s, such studies, mainly postmarketing
studies of newly licensed drugs, had a questionable
reputation because they were often misused as a mar-
keting instrument: physicians were offered money for
observing the effects of a new drug that they were sup-
posed to prescribe—mainly with meaningless results.
However, observational studies without such distort-
ing influence and with a scientifically based method-
ology
18 may yield valuable additional knowledge to the
results of controlled clinical trials.
19 The aims of such
trials could be to gain knowledge about: (i) prescrib-
ing behaviors, etc; (ii) undesirable drug effects of rou-
tinely administered drugs under real-world conditions,
eg, interactions with other drugs in multimedicated
patients with chronic diseases; (iii) the course of the
treatment.
18
According to the recommendations of the German
Federal Institute for Drugs and Medicinal Products
18 the
nonintervention of an observational study is character-
ized by the separation of the inclusion of patients into
the study from the prior decision on the treatment that
will follow usual medical practice. Scientifically sound
prospective observational trials should use systematic
and standardized observations and a schedule for 
data analysis laid down prior to the observations.
Observational studies are not clinical trials, and the
researcher is not obliged to apply for the vote of an EC.
However, he or she is advised to consult an EC, and is
obliged to do so if he or she uses procedures beyond the
mere routine treatment, eg, a specific questionnaire.
Also additional information to the usual information of
a patient for his/her consent to treatment should be
given, at least regarding the fact that the patient will be
included in a study and about the confidentiality of his
or her recorded data according to data protection laws. 
Screening procedures and the problem of incidental
findings 
Screenings almost always result in unexpected inciden-
tal findings. A currently highly debated example is that
of incidental findings with magnetic resonance imaging
(MRI): increasing breadth of applications of brain MRI
in healthy, ie, asymptomatic people for various reasons
such as research, occupational or clinical screening, or
commercially for reassurance of good health
20 yielded
clinically significant incidental findings in 2% to 3%;
these were primarily neoplastic or vascular in nature.
21
These evidence-based data provoke questions: how to
deal with incidental findings in banked data and how to
interpret individual findings that fall outside a norma-
tive range yielded by group-averaged functional images,
and particularly how to deal with such findings towards
“study participants, patients and consumers to enable
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them to navigate through the labyrinth of information
about incidental findings in research, clinical care, and
the rapidly evolving industry of personalized medicine.”
“Information available online to the self-guided user is
noisy and unreliable.” Therefore, “the professional com-
munity has the duty to ensure that rational decisions can
be made,” especially because such findings “might
become a part of a person’s life. Questions about antic-
ipating and managing such finding must be explicitly and
systematically encouraged.”
20
Until now neither the law nor governmental regulations
as well as ECs offer clear guidance to researchers on
handling unexpected findings
22,23 and a frame for partic-
ipants to contextualize their expectations.
24 However,
there seems to be agreement that before screening pro-
cedures for research studies the potential research sub-
ject should be informed about the possibility of an inci-
dental finding and how to deal with it. We preferred to
obtain the consent of the research participant that we
might inform his/her practitioner about unexpected and
perhaps clinically relevant findings, because the practi-
tioner—knowing the patient and his/her context —is
better equipped to judge the clinical significance of the
finding and how to convey the information to the sub-
ject.
25This is particularly valid if the researcher is not a
clinician or has no specific competence, eg, in evaluat-
ing functional MRI images. If the potential research
subject refuses to have such information transmitted to
his/her practitioner or if he/she has no physician at all,
the information about the possibility of an unexpected
finding and its potential and perhaps severe conse-
quences for the individual’s life (Kerr 1995, cited in refs
26,27) must be given explicitly and in detail, in order to
enable the subject to make a rational decision. If an
incidental finding of potential clinical relevance is dis-
covered, the subject should be advised to consult a
physician as soon as possible. A comprehensive analy-
sis of handling incidental findings in brain imaging has
resulted in a range of options, examples of key points,
and practical guidelines.
28 An early example of a
detailed information procedure, particularly explicit
information prior to testing and psychological counsel-
ing before and after the test, has been elaborated for
genetic screening for Huntington’s disease,
29 and then
for all genetic testing,
30 and will get much more impor-
tance with the rapidly evolving availability of affordable
genetic testing of the whole genome (“the $1000
genome”). 
Surveys
Surveys on psychiatric morbidity in a population must
consider possible psychological risks by the mode of con-
tacting and questioning the participants or by the content
of questionnaires, eg, intimate questions, but also how to
deal with difficult findings such as demand for help, ille-
gal behavior, or child abuse.
1 Major precautions must be
implemented to protect confidentiality, ie, anonymization
and safeguarding of data according to data protection
laws and guidelines, eg, European standards on confi-
dentiality and privacy in Healthcare 2006.
31
Ethical implications
These examples have demonstrated the ethical signifi-
cance of risk-benefit-assessment in order to avoid a vio-
lation of the ethical principle of nonmaleficence and the
importance of adequate information of potential study
participants in order to enable them to make rational
decisions, ie, to respect the ethical principle of self-deter-
mination. Both core components of ethical implications
of research with human beings will be discussed now in
a more general framework, but with specific reference
to research interventions in mentally ill patients, and par-
ticularly in those who are incompetent to provide con-
sent. Clinical research is understood as an intervention
in human beings that aims by scientific methods sys-
tematically to achieve supraindividual knowledge, and
thereby goes beyond the individual benefit of the par-
ticipating person. Such research intervention is ethically
acceptable only: (i) if its risk:benefit ratio is acceptable,
and (ii) if the informed consent is valid.
Risk:benefit ratio
Proportionality of the risk:benefit ratio
This ethical core requirement of a clinical research inter-
vention means that the relationship between its potential
benefits and risks is reasonable and justified and does not
violate good practice. Without these preconditions a
research intervention is not permissible, even if compe-
tent probands consent to participate in the research inter-
vention. On the other hand, even risky interventions or
those without a potential direct individual benefit may
be ethically justified if competent persons consent, eg, in
phase I trials in healthy people, and particularly in nat-
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able balanced relationship
32 in cases with only a future or
no direct potential individual benefit but with potential
risks such as objective physical risks or psychological bur-
dens. “Risk-benefit ratios often cannot be calculated,
even roughly.” 
33 The final report of the US National
Advisory Bioethics Commission (NABC) stated in 2001:
“An IRB may approve a research proposal only if it
judges that the risks are reasonable in relation to poten-
tial benefits. This judgement may be an IRB’s single most
important and difficult determination, because it ensures
that when research participants voluntarily consent to
participate in a research study, they are offered a “rea-
sonable choice’’ (cited from ref 23). Unfortunately, as the
NBAC notes: “current regulations do not further elabo-
rate how risks and potential benefits are to be assessed,
and little additional guidance is available to IRBs.” 
34
Furthermore, there exist discrepancies between guide-
lines: whereas this NABC report states that risks must be
reasonable in relation to potential benefits, others
demand absolute limits for risks such as potential irre-
versible damage or death, and no more than minimal
risks in incompetent research participants. 
Due to the difficulties of judgement Research Ethics
Committees (RECs) tend to avoid such in-depth eval-
uation of the risk-benefit relationship and focus on other
aspects of the study, such as the consent process as
Simonsen found out in his 3-year observational study of
Swedish RECs.
32This may be especially the case in nat-
uralistic trials with at best minor benefits such as reward-
ing altruistic feelings of participants by serving others or
the social good but with some generally unexpected
potential burdens or even risks. A careful evaluation
implies a clear understanding of the uncertainties in
establishing (i) potential benefits and (ii) potential risks
and/or burdens and/or inconvenience for the participat-
ing individual as well as for other present or future
patients (social value),
Benefits and risks
Both benefits and risks must be considered on the indi-
vidual as well as on the social level.
Social benefit
The aim of research with human beings in the field of
mental health is scientifically based knowledge with the
final objective of improving the treatment and care of ill
people (in the best case successfully also for the partici-
pating individuals), either directly by controlled trials or
indirectly by naturalistic, eg, epidemiological trials for
the planning of services or case-control trials for knowl-
edge of risk factors for disorders. The important social
value of this objective is evidenced directly or indirectly
by legal norms such as laws and guidelines, eg, the
German social law (SGB V) provides that insurance
companies are permitted to pay only for medical inter-
ventions with established economic efficacy and advis-
ability, and correspondingly physicians are obliged to
prescribe only indicated, effective, and economical inter-
ventions. Consequently it is a societal demand to prove
scientifically the “efficacy” (or “effectiveness” under
conditions of clinical routine or in practice), and the
“efficiency” of medical interventions, ie, the relationship
of therapeutic effectiveness to its costs, both medically
in terms of side effects and risks and economically in
terms of financial burdens. This societal demand must be,
of course, fairly balanced with the protection of the indi-
vidual research participant against risks, burdens, and
inconvenience, particularly in vulnerable individuals. 
Individual benefit
However, due to the legally founded conviction in lib-
eral Western societies that no human being is obliged to
sacrifice him- or herself for the community (“In medical
research involving human subjects, the well-being of the
individual research subject must take precedence over
all other interests.”—§6, Declaration of Helsinki/Seoul
2008) the practice of clinical research is dominated not
by the social value of clinical research but by the impres-
sion of individual benefits of the participating research
subjects such as:
￿ Gaining a better intervention that is more effective,
acts more rapidly, or has fewer side effects than the
existing standard intervention
￿ Satisfying his or her altruistic feelings of solidarity with
other ill people
35
￿ Earning money
36 or other privileges.
Further motivational factors are a feedback about one’s
own illness and its status, feeling autonomous and self-
determined and the wish for other people to have a bet-
ter understanding of one’s own mental state.
Particularly with incompetent patients with mental ill-
ness the motivation of their caregivers and guardians is
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that aim to improve the ill person’s quality of life and/or
to lessen the burden for the caregiver.
37,38
Risks, burdens, and inconvenience
If an individual participates in a necessary and legally
required research study for the best of all, of course, this
individual must be protected against risks and burdens
of the research intervention. A variety of normative reg-
ulations prescribes the content, extent, and mode of this
protection of research participants against risks. 
The heading of “risk” comprises: (i) objective threats to
the individual proband, eg, undesirable side effects of the
intervention; prolongation of suffering or worsening of
the disorder due to the withholding of a specific treat-
ment in a placebo-control group; and in a broader sense
also dispositions for undesirable effects, eg, pharmaco-
genetic or allergic dispositions or those that are related
to noncompliant personalities, as well as (ii) subjective
burdens and inconvenience, eg, by overly rigorous
research procedures or a feared risk such as stigmatiza-
tion, particularly in depressed patients and drug abusers,
which may demotivate potential research participants. 
Risks and side effects of an intervention are objectifiable
effects in contrast to burdens and inconvenience, which
are much more of a subjective, individual specific char-
acter. Therefore, the researcher should explore specifi-
cally or should at least be aware of the research partic-
ipant’s potential individual sensitivity to both physical
and psychic burdens that are specifically related to the
intervention.
However, risks for society should also be considered, eg,
the progression of hitherto untreatable conditions, or if
research interventions do not precisely follow the reg-
ulatory requirements and thereby lead to incidents and
undermine the necessary trust of the public; this may
prolong or even prevent the recruitment of individuals
for research interventions that aim for the gain of
needed knowledge.
Standards of benefits and risks
These can be determined more precisely only in refer-
ence to a factor such as reduction of symptoms or suf-
fering or an increase in the quality of life. Individual ben-
efit may comprise the improvement of welfare or
well-being as well as the best interest of the research
participant, ie, both subjectively experienced benefits
and objective benefits seen from outside. Social benefit
is related to the gain of knowledge. 
The reduction or increase of more complex concepts
such as suffering or the quality of life are clearly more
difficult to be operationalized as a requirement for the
assessment of the size of a benefit. Terms such as the
“prospect” of benefit, or a “direct,” “important,” or “sig-
nificant” benefit for the participating research subject or
the gain of “essential” knowledge are not clearly defined
or—as undetermined terms of law— not definable at all
and thereby open for subjective interpretations.
39,40
Standards comprise, among other aspects, strength and
limits. Strength of risks is described by a broad range of
grading terms such as “without the danger of impair-
ment”, minimal risk, minor increase of minimal risk, “not
insignificant risks”, “serious risk to health”, “possible
irreversible damages,” risks of unacceptable dimensions.” 
41
Absolute upper limits of risks for research participants
are irreversible impairments and death. Standard lim-
its for research with incompetent patients are no more
than “minimal risk,” “minor increase of minimal risk”
and “direct prospective benefit,” 
42,43 terms which are
under discussion.
Assessment of the risk:benefit relationship
The assessment of the strength and probability of poten-
tial risks and burdens as well as of potential benefits and
particularly their relationship to each other is the crucial
step in evaluating the acceptability of a research inter-
vention. It is filled with uncertainties (and difficulties in
conveying its result to the potential research partici-
pant)
40,42: “accordingly, the estimation of the reasonable-
ness of a risk:benefit ratio depends upon normative val-
ues and conventions.”
Thereby, different standards for the evaluation have
been developed, as is evidenced by a recent controversy
between representatives of the “equipoise” standard (eg,
ref 44) and those of a “net-risks-test.” 
43,45
Validation of the risk:benefit ratio 
With regard to the uncertainties of risk-benefit estimates,
a safe validation of consent should be observed by a
three-step evaluation of the requirement of acceptabil-
ity of potential risks and burdens in relation to the
expected benefits of a research intervention:
Clinical research
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1. First the researcher must give reasons for considering
the relationship of risks and burdens of his or her
planned research intervention as acceptable, ie, as rea-
sonable and justified.
2. Then the Research Ethics Committee (REC) must
evaluate this relationship with regard to legal and eth-
ical norms and professional expertise, and should give
reasons—at least in research studies with vulnerable
subjects—not only for refusal but also in case of
acceptance of the research application and particu-
larly of the ethical considerations of the applying
researcher. 
3. Finally the potential research participant or his or her
legal guardian must evaluate the institutionally
approved acceptable relationship of potential risks,
burdens, and inconvenience to the expected benefits
of the research study with regard to his or her per-
sonal idiosyncrasies, interests, and values, and in case
of his or her individual acceptability of the relation-
ship he or she may consent to participate. 
Informed consent
All medical interventions in human beings must be
authorized personally by the concerned individual. This
is particularly important for a research intervention
because it is aimed not only for the benefit of the indi-
vidual but also or even only at the benefit of others. This
is much less regulated in naturalistic studies, although
they offer no or at best minor individual benefit but
potentially considerable risks, eg, with unexpected inci-
dental findings. 
Therefore, the basic precondition for research with
human beings is their voluntary and valid informed con-
sent. However, the voluntariness may be jeopardized by
conditions such as imprisonment, poverty, or personal
dependency, and the validity may be impaired by insuf-
ficient information, its inadequate understanding, or
incapability of making decisions. Populations with such
risk factors are called vulnerable populations. Mentally
ill persons are a vulnerable population. Their specific
vulnerability is given by the risk that their competence
to consent may be impaired or does not exist at all. In
such conditions they are at risk to be used without
authorization for other than their own benefit. This may
also happen in naturalistic studies, eg, in those that
include children, but in general participants of such stud-
ies are healthy adults with competence to consent.
Nevertheless, the researcher and the design of the study
should be aware of the possible incapacity of potential
participants in order to deal with it.
The underlying concept of informed consent is that the
consenting research participant makes the objective of
the research intervention his or her own. However, prac-
tice is more or less distant from this concept, particularly
with incompetent patients, eg, with minors or mentally
ill people. 
Assessment of capacity to consent
Details and open questions of the informed consent
process are eg, embedding it into the development of
the physician-patient-relationship and improving the
patient’s capacity to understand and to consent, partic-
ularly the assessment of the capacity.
39 Recently a broad
range of instruments for a standardized assessment of
the capacity to consent has been developed, but up to
now its application is limited by a restricted practica-
bility or unproven validity or specific indications for
only some dimensions of the capacity to consent.
46,47
Some of them focus not only on understanding infor-
mation but also on both intentional and emotional
influences on the capacity to consent, and on attitudes
of relatives and caregivers as well as personal depen-
dency on them. Even if the capacity to consent is
impaired, the researcher should try to obtain at least an
assent as an expression of respect for the patient and as
a trust-building measure, whereas a dissent of an incom-
petent patient must be respected in any case.
Particularly patients who are in remission from an
episode of mental illness and/or who have regained the
capacity to consent, as well as patients in early stages of
a progressive neurodegenerative disease but still with
the capacity to consent should be encouraged and
empowered to develop an advance directive for med-
ical interventions in situations to be expected in the
future, eg, relapses/recurrences or the worsening of the
illness, in which their capacity to consent may be
impaired. If possible and acceptable with regard to the
value profile of the patient he/she should be asked to
include a statement on a possible participation in a
research project in this advance directive.
48
Information on the risk:benefit ratio of the research
intervention to the potential research participant (or his
authorized guardian) is a core requirement of obtaining
a valid consent. 
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1. Ethical questions of research with human subjects
must be answered not only for controlled trials but
also for naturalistic trials as well. They are related to
risk-benefit-assessment and to informed consent.
2. Informing the patient is not only a legal requirement
but much more a chance to develop trust. (The patient
who is armed with information, who wants to ask
questions, should be seen as an asset in the process of
care and not an impediment to it.” (Donaldson, cited
in ref 49). It needs time and should be considered in
planning the research study. In particular, vulnerable
research participants should be empowered at least to
assent to the research procedure besides the substi-
tuted informed consent by authorized persons. 
3. Mentally ill patients with still maintained (eg, in neu-
rodegenerative diseases) or regained capacity to con-
sent after an illness episode should be encouraged to
develop an advance directive for medical interven-
tions including a possible participation in a research
project. 
4. Assessment of competence to consent is needed to be
sure of the validity of consent. However, there is still
a lack of both scientifically proven and practicable
standardized tests which should be overcome by fur-
ther research.
5. Consent should be related to the relevant matter in
question. Occasionally it will be considered also to
relate the threshold for acceptance of the competence
to consent to the risk of an intervention. In practice
this may be a valid consideration in order to avoid an
uncritical consent of a patient to a risky intervention.
However, it requires a more differentiated risk-ben-
efit estimation in research: the possible benefit of
increasing the threshold of acceptance the compe-
tence to consent for the protection of the research par-
ticipant is opposed by the possible risk that his/her
guardian authorized due to his/her supposed incom-
petence will consent to an intervention with a greater
risk than that to which the competent patient would
have been consented. In such a case it should be
examined whether the authorized guardian orients
his/her decision exclusively by the presumed will of
the patient.
6. Benefits and risks are undetermined terms of law, and
should be determined explicitly as clearly as possible
in each specific research design.
7. With regard to the uncertainties of risk-benefit esti-
mates a safe validation of consent should be observed
by a three-step evaluation (researcher, REC, patient)
of it.
8. Researchers should be educated systematically on the
ethical implications of clinical research. In October
2009 a workshop of the European Science Foundation
made clear that “there is an urgent need to develop
consistent education in conduct of research (RCR).”
50
All regulations should be observed thoroughly in
order not to lose the trust of both the research partic-
ipant and the public in research, which is a basic
requirement of successful recruitment of vulnerable
individuals.  ❏
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